Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 367 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Pregnant Women Clear all

Conditions: Kidney Disease
Interventions: Propranolol, Losartan, Eprosartan; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Endometrial Cancer
Interventions: behavioral dietary intervention, exercise intervention, counseling intervention, educational intervention, survey administration; Behavioral · Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Renal Impairment, Renal Insufficiency, Kidney Disease, Kidney Diseases
Interventions: IDN-6556; Drug
Lead sponsor: Conatus Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 2
States / cities: DeLand, Florida • Miami, Florida

Conditions: Staphylococcus Aureus
Interventions: CA-MRSA Decolonization; Other
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: Female only
Enrollment: 107 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Urethritis, Healthy Men Age 18-50 With no Urethral Symptoms
Interventions: Colli-Pee, standard of care 60 mL urine cup, Urinalysis, Sysmex UP-5000; Device · Diagnostic Test
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Renal Impairment
Interventions: Lemborexant; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Healthy Volunteer Study
Interventions: CBP-4888, Placebo; Drug · Other
Lead sponsor: Comanche Biopharma; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy, Renal Impairment
Interventions: Enlicitide; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 5
States / cities: Edgewater, Florida • Hallandale, Florida • Inverness, Florida + 2 more

Conditions: Healthy
Interventions: PF-04634817; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Cancer, Breast, Cancer, Uterus, Cancer, Ovary, Obesity, Activity, Motor, Diet, Healthy
Interventions: With Love, Grandma ("Con Cariño, Abuelita"); Behavioral
Lead sponsor: University of Miami Sylvester Comprehensive Cancer Center; Other
Eligibility: 21 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Urinary Tract Infections
Interventions: E. coli Nissle 1917; Drug
Lead sponsor: Elizabeth Lucas; Other
Eligibility: 21 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Focal Segmental Glomerulosclerosis (FSGS)
Interventions: IXP; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 3
States / cities: Miami, Florida • St. Petersburg, Florida • San Antonio, Texas

Conditions: Obstetric Labour, Premature, Premature Labor
Interventions: GSK221149A; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 30 Years to 55 Years · Female only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy, Myocardial Fibrosis, Chronic Kidney Disease
Interventions: Arm 1 MRI with gadolinium; Drug
Lead sponsor: Moriel Vandsburger; Other
Eligibility: 20 Years to 80 Years
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Acute Kidney Injury (Nontraumatic)
Interventions: CXA-10 emulsion, Placebo; Drug
Lead sponsor: Complexa, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Renal Insufficiency
Interventions: PF-04634817; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 2
States / cities: DeLand, Florida • Miami, Florida

Conditions: Preeclampsia, Maternal, Hypertension, Pregnancy
Interventions: Sphygmomanometer; Device
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Orange, California

Conditions: Healthy, Chronic Kidney Diseases
Interventions: Definity, Super-resolution ultrasound imaging; Drug · Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Jacksonville, Florida • Rochester, Minnesota

Conditions: Chronic Fatigue Syndrome, Fibromyalgia, Gulf War Illness, Multiple Chemical Sensitivity, Interstitial Cystitis, Irritable Bowel Syndrome
Interventions: Not listed
Lead sponsor: Georgetown University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: End Stage Renal Disease
Interventions: Lanthanum carbonate Granule Formulation, Lanthanum carbonate Chewable Tablets (Fosrenol); Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Cypress, California

Conditions: Renal Insufficiency, Healthy
Interventions: Canagliflozin (JNJ-28431754); Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 3
States / cities: Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee

Conditions: Healthy, Pregnancy
Interventions: Not listed
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 21 Years and older · Female only
Enrollment: 320 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2024
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Obstetric Labour, Premature
Interventions: Retosiban solution for Infusion, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 20 Years to 45 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Glendale, California

Conditions: PCOS (Polycystic Ovary Syndrome), Obese Adolescents, Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities, Overweight Adolescents, Irregular Menstrual Cycle, Irregular Menstrual Cycles, Hirsutism, Hyperandrogenism
Interventions: Beef+; Other
Lead sponsor: Texas A&M University; Other
Eligibility: 11 Years to 17 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: College Station, Texas

Search by objective public record fields.

Pharmacokinetic Study in Patients With Chronic Kidney Disease and Healthy Volunteers

Exercise and Healthy Diet or Standard Care in Patients in Remission From Stage I or Stage II Endometrial Cancer

PK and PD Study of IDN-6556 in Subjects With Severe Renal Impairment and Matched Healthy Volunteers

A Prospective Cohort Pilot Study of the Clinical and Molecular Epidemiology of Staphylococcus Aureus in Pregnant Women at the Time of Group B Streptococcal Screening in a Large Urban Medical Center in Chicago, IL USA

Establishing Baseline Sysmex UF-5000 Flow Cytometer Results in Healthy Men

Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Normal Renal Function or With Severe Renal Impairment

Study of CBP-4888 in Healthy, Non-Pregnant Female Subjects

A Clinical Study of Enlicitide in Participants With Severe Renal Impairment (MK-0616-032)

A Multiple Dose Study To Determine Safety, Tolerability, and Pharmacokinetics Of PF-04634817 In Healthy Adult Subjects

With Love, Grandma ("Con Cariño, Abuelita") Pilot Study

Open Label Trial of Nissle 1917

Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic Impairment

Absorption, Distribution, Metabolism And Excretion Study For GSK221149A

Molecular MRI of the Fibrotic Heart

Study of CXA-10 in Healthy Volunteers

PF-04634817 Renal Impairment Study

A Comparison of BNP Levels Using the Nexfin Device in Healthy Pregnant and Preeclamptic Women

A Study of Renal Microvessel Imaging for Chronic Kidney Disease

Proteomics of Cerebrospinal Fluid in Chronic Fatigue Syndrome

Pharmacodynamic Study of Two Lanthanum Carbonate Formulations in Healthy Adults

A Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Volunteers With Varying Degrees of Kidney Function

Fetal Programming of Obesity

Study to Investigate the Pharmacokinetics (PK), Safety and Tolerability of Retosiban in Healthy Japanese Women

Lean Beef as Part of a Healthy Meal Plan in Adolescents With Polycystic Ovary Syndrome (PCOS)/Polyendocrine Metabolic Ovarian Syndrome (PMOS)